FierceBiotechOriginal article
{"a":[{"_":"Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs","$":{"href":"/research/axioms-wharton-jelly-stem-cell-therapy-posts-positive-phase-1-data-newborn-brain-injury","hreflang":"en"}}]}
Phase 1positivePositive
AI Analysis
Summary
Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in a Phase 1 trial for potentially fatal newborn neurological diseases. The company believes this validates their approach to targeting brain disorders, addressing challenges that have affected other stem cell biotechs.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
0% mortality rate over two years in potentially fatal newborn neurological diseases
Importance:6/10
Sentiment:
0.85
stem cell therapyWharton jellynewborn brain injuryneurological diseasesmortality rate
Related Companies
Read the original article
Published by FierceBiotech on July 15, 2026 9:46 AM